Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lifeward Ltd.

NASDAQ: LFWD · Industrial Applications and Services · 7 alerts · CIK 1607962

Share price
$3.62Close, Nov 16
Market cap
$10.3M
Shares outstanding
2.84MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lifeward Ltd. filings on SEC EDGAR ↗

9:26 AM ET 8-K
Financial Results

Lifeward Financial Results

Lifeward Ltd. reported Q3 2026 financial results, highlighted by an 18% year-over-year increase in AlterG revenue to $3.6 million. The company is transitioning its ReWalk exoskeleton business to a capital-efficient channel-partner distribution model, including a pilot program with Ottobock Care, to expand patient access and reduce operating expenses.

Term
Q3 2026

“Our third quarter results reflect the continued momentum of AlterG, which delivered its second consecutive quarter of double-digit year-over-year revenue growth. We are also making significant progress in our strategic transition of ReWalk to a channel-partner model, which we believe is the most effective way to scale this business and bring our life-changing technology to more patients.”

Larry Jasinski, Chief Executive Officer

“We remain focused on driving commercial execution and managing our resources effectively as we advance our transition to a channel-partner model for ReWalk. We believe this model will allow us to reach more patients while improving our operating efficiency and cash flow over the long term.”

Ronen Tsimerman, Chief Financial Officer
9:23 AM ET 10-Q
Financial Results

Lifeward Q3 2026 Results: Net Loss of $5.05M, Loss Widens

Lifeward Ltd. reported its financial results for the quarter ended September 30, 2026, highlighting the recent acquisition of Oratech Pharmaceuticals Ltd. and the ongoing transition to a channel-partner distribution model. The company expressed substantial doubt regarding its ability to continue as a going concern, noting the urgent need for additional financing to fund operations and clinical trials for ORMD-0801.

Key figure
Net loss $5.05M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.